

**CLAIMS:**

1. A method for treatment of a psychiatric disorder, disease or condition, which comprises administering to an individual in need of such a treatment an effective amount of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).  
5
2. A method according to claim 1 wherein said individual is immunized with a therapeutically effective amount of an agent selected from the group consisting of Copolymer 1, a Copolymer 1-related peptide, and a Copolymer 1-related polypeptide.  
10
3. The method according to claim 1 or 2 wherein said agent is Copolymer 1.
4. The method according to claim 1 or 2 wherein said agent is a Copolymer 1-related peptide or a Copolymer 1-related polypeptide.
- 15 5. The method according to claim 1 wherein said agent are T cells which have been activated by Copolymer 1.
6. A method according to claim 1 or 2 wherein said psychiatric disorder, disease or condition is selected from the group consisting of: (i) anxiety disorders, that include phobic disorders, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), acute stress disorder and generalized anxiety disorder; (ii) mood disorders, that include depression, dysthymic disorder, bipolar disorders and cyclothymic disorder; (iii) schizophrenia and related disorders such as brief psychotic disorder, schizophreniform disorder, schizoaffective disorder and delusional disorder; (iv) drug use and dependence such as alcoholism, opiate dependence, cocaine dependence, amphetamine dependence, hallucinogen dependence, and phencyclidine use; and (v) memory loss disorders such as amnesia  
20  
25

or memory loss associated with Alzheimer's type dementia or with non-Alzheimer's type dementia, e.g. multi-infarct dementia or memory loss associated with Parkinson's disease, Huntington's disease, Creutzfeld-Jakob disease, head trauma, HIV infection, hypothyroidism and vitamin B12 deficiency.

5 7. The method according to claim 6 wherein said psychiatric disorder is schizophrenia.

8. The method according to claim 6 wherein said psychiatric disorder is an anxiety disorder such as stress or post-traumatic stress disorder

9. The method according to claim 6 wherein said psychiatric disorder is a mood 10 disorder such as depression or a bipolar disorder.

10. A pharmaceutical composition for treatment of a psychiatric disorder, disease or condition comprising a pharmaceutically acceptable carrier and an active agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated 15 with (i), (ii) or (iii).

11. The pharmaceutical composition according to claim 10, wherein said active agent is Copolymer 1.

12. The pharmaceutical composition according to claim 11, wherein said agent is a Copolymer 1-related peptide or a Copolymer 1-related polypeptide.

20 13. The pharmaceutical composition according to any one of claims 10 to 12 wherein said psychiatric disorder, disease or condition is selected from the group consisting of: (i) anxiety disorders, that include phobic disorders, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), acute stress disorder and generalized anxiety disorder; (ii) mood disorders, that include depression, 25 dysthymic disorder, bipolar disorders and cyclothymic disorder; (iii) schizophrenia and related disorders such as brief psychotic disorder, schizophreniform disorder,

schizoaffective disorder and delusional disorder; (iv) drug use and dependence such as alcoholism, opiate dependence, cocaine dependence, amphetamine dependence, hallucinogen dependence, and phencyclidine use; and (v) memory loss disorders such as amnesia or memory loss associated with Alzheimer's type dementia or with  
5 non-Alzheimer's type dementia, e.g. multi-infarct dementia or memory loss associated with Parkinson's disease, Huntington's disease, Creutzfeld-Jakob disease, head trauma, HIV infection, hypothyroidism and vitamin B12 deficiency.

14. The pharmaceutical composition according to claim 13 wherein said psychiatric disorder is schizophrenia.

10 15. The pharmaceutical composition according to claim 13 wherein said psychiatric disorder is an anxiety disorder such as stress or post-traumatic stress disorder

16. The pharmaceutical composition according to claim 13 wherein said psychiatric disorder is a mood disorder such as depression or a bipolar disorder.

15 17. A vaccine for immunization of an individual suffering from a psychiatric disorder, disease or condition comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1-related peptide, and a Copolymer 1-related polypeptide.

18. The vaccine according to claim 17 wherein said active agent is Copolymer 1.

20 19. The vaccine according to claim 17 wherein said agent is a Copolymer 1-related peptide or a Copolymer 1-related polypeptide.

20. The vaccine according to any one of claims 17 to 19 wherein said vaccine comprises the active agent without an adjuvant.

25 21. The vaccine according to any one of claims 17 to 19 wherein said vaccine comprises the active agent emulsified in an adjuvant suitable for human clinical use.

22. The vaccine according to claim 21 wherein said adjuvant is selected from the group consisting of aluminum hydroxide, aluminum hydroxide gel, and aluminum hydroxyphosphate.

23. The vaccine according to claim 17 for immunization of an individual  
5 suffering from a psychiatric disorder, disease or condition selected from: (i) anxiety disorders, that include phobic disorders, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), acute stress disorder and generalized anxiety disorder; (ii) mood disorders, that include depression, dysthymic disorder, bipolar disorders and cyclothymic disorder; (iii) schizophrenia and related disorders such as  
10 brief psychotic disorder, schizophreniform disorder, schizoaffective disorder and delusional disorder; (iv) drug use and dependence such as alcoholism, opiate dependence, cocaine dependence, amphetamine dependence, hallucinogen dependence, and phencyclidine use; and (v) memory loss disorders such as amnesia or memory loss associated with Alzheimer's type dementia or with non-  
15 Alzheimer's type dementia, e.g. multi-infarct dementia or memory loss associated with Parkinson's disease, Huntington's disease, Creutzfeld-Jakob disease, head trauma, HIV infection, hypothyroidism and vitamin B12 deficiency.

24. The vaccine according to claim 23 wherein said psychiatric disorder is schizophrenia.

20 25. The vaccine according to claim 23 wherein said psychiatric disorder is an anxiety disorder such as stress or post-traumatic stress disorder.

26. The vaccine according to claim 23 wherein said psychiatric disorder is a mood disorder such as depression or a bipolar disorder.

27. Use of an agent selected from the group consisting of (i) Copolymer 1, (ii) a  
25 Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii), for the preparation of a pharmaceutical composition for treatment of a psychiatric disorder, disease or condition.

28. Use of an agent selected from the group consisting of Copolymer 1, a Copolymer 1-related peptide, and a Copolymer 1-related polypeptide, for the preparation of a vaccine for immunization of an individual suffering from a psychiatric disorder, disease or condition.

5 29. Use according to claim 28 wherein said vaccine comprises the active agent without an adjuvant.

30. Use according to claim 28 wherein said vaccine comprises the active agent emulsified in an adjuvant suitable for human clinical use.

10 31. Use according to claim 20, wherein said adjuvant is selected from the group consisting of aluminum hydroxide, aluminum hydroxide gel, and aluminum hydroxyphosphate.

32. Use according to any one of claims 27 to 31 wherein said active agent is Copolymer 1.

15 33. Use according to any one of claims 27 to 31 wherein said active agent is a Copolymer 1-related peptide or a Copolymer 1-related polypeptide.

20 34. Use according to claim 27 or 28 wherein said psychiatric disorder is selected from: (i) anxiety disorders, that include phobic disorders, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), acute stress disorder and generalized anxiety disorder; (ii) mood disorders, that include depression, dysthymic disorder, bipolar disorders and cyclothymic disorder; (iii) schizophrenia and related disorders such as brief psychotic disorder, schizophreniform disorder, schizoaffective disorder and delusional disorder; (iv) drug use and dependence such as alcoholism, opiate dependence, cocaine dependence, amphetamine dependence, hallucinogen dependence, and phencyclidine use; and (v) memory loss disorders such as amnesia or memory loss associated with Alzheimer's type dementia or with non-Alzheimer's type dementia, e.g. multi-infarct dementia or memory loss

associated with Parkinson's disease, Huntington's disease, Creutzfeld-Jakob disease, head trauma, HIV infection, hypothyroidism and vitamin B12 deficiency.

35. Use according to claim 34 wherein said psychiatric disorder is schizophrenia, an anxiety disorder such as stress or post-traumatic stress disorder, or a mood disorder such as depression or a bipolar disorder.

5        36. An article of manufacture comprising packaging material and a pharmaceutical composition contained within the packaging material, said pharmaceutical composition comprising an agent selected from the group consisting of Copolymer 1, a Copolymer 1-related peptide, and a Copolymer 1-related polypeptide; and said packaging material includes a label that indicates that said agent is therapeutically effective for treating a psychiatric disorder.

10      37. An article of manufacture comprising packaging material and a pharmaceutical composition contained within the packaging material, said pharmaceutical composition comprising Copolymer 1; and said packaging material includes a label that indicates that Copolymer 1 is therapeutically effective for 15 treating a psychiatric disorder.

15      38. The article of manufacture of claim 36 or 38 wherein said psychiatric disorder is selected from: (i) anxiety disorders, that include phobic disorders, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), acute stress disorder and generalized anxiety disorder; (ii) mood disorders, that include depression, dysthymic disorder, bipolar disorders and cyclothymic disorder; (iii) schizophrenia and related disorders such as brief psychotic disorder, schizophreniform disorder, schizoaffective disorder and delusional disorder; (iv) drug use and dependence such as alcoholism, opiate dependence, cocaine dependence, amphetamine dependence, hallucinogen dependence, and phencyclidine use; and (v) memory loss disorders such as amnesia or memory loss associated with Alzheimer's type dementia or with non-Alzheimer's type dementia, e.g. multi-infarct dementia or memory loss associated with Parkinson's disease,

Huntington's disease, Creutzfeld-Jakob disease, head trauma, HIV infection, hypothyroidism and vitamin B12 deficiency.